SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid speculation about its potential role in powering AI data centers, driving a surge in the stock price. While some celebrate technical breakouts and upside potential, others caution about bubble risks given the company's pre-revenue status and high valuation. Community chatter revolves around whether the hype is justified or if a correction is imminent.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies to "buy the dip," viewing current price levels as a discount before a potential exchange listing; many in the community believe it's poised for a significant rebound. Token burns and staking mechanisms are heavily discussed as potential catalysts. Community members are actively dismissing negative sentiment, emphasizing the project's resilience and long-term vision within the Solana meme coin ecosystem.

AGM Group Holdings, Inc. is a technology company, which engages in the provision of financial solutions. It focuses on the research and development of blockchain-oriented ASIC chip, production of encryption mining machines, and financial technology software services. Its products and services include technology hardware research and development, and assembling and sales of technology hardware. The company was founded by Zhen Tao Jiang and Wen Jie Tang on April 27, 2015 and is headquartered in Hong Kong.

AGM Group Holdings Inc - Ordinary Shares - Class A

AGMH is trending as traders discuss its recent surge, potentially driven by news regarding the purchase of BTC miners. Community members are pointing to its low float and high short interest as contributing factors, while others suggest it could be part of a broader Hong Kong-related stock trend. Some traders are also comparing it to other high-flying stocks, while cautioning about potential volatility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as part of a broader surge in quantum computing stocks, possibly fueled by news of a recent Air Force contract and progress in DARPA's Quantum Benchmarking Initiative. The community is actively debating whether the stock is overvalued and ripe for profit-taking or if it has more room to run, with some speculating about potential mergers or acquisitions in the sector. Talk of short squeezes, government contracts, and fidelity milestones has also been circulating among investors.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as discussions revolve around its potential participation in a White House-backed eVTOL pilot program and the implications of a military pivot with Anduril, with some seeing it as undervalued compared to peers like Joby. The community is closely watching for news catalysts, FAA progress, and key price levels that could trigger a short squeeze, while also debating the stock's long-term potential.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as part of a broader conversation around quantum computing stocks, with community members discussing its potential for a range break. Some traders believe NXXT is accumulating shares on dips, while others express skepticism about the sector's current valuations and commercial viability. Bullish investors cite news catalysts expected before year-end and the potential for a short squeeze, while bears point to the company's minimal revenue.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is trending as the community speculates about an upcoming IPO, driven by comments from insiders and analysts suggesting a potential public offering soon; excitement is further fueled by positive price target updates. Community members are actively discussing strategies around holding shares through the IPO, the potential for significant gains, and the possibility of government actions affecting shareholder value. Chatter revolves around the balance between short-term volatility on the OTC market and long-term potential upon relisting on a major exchange.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amid discussions about its valuation, growth potential, and analyst price targets, with some community members expressing bullish sentiment and anticipating a rebound. The stock's movement is also being attributed to broader market factors and potential impacts from coffee tariffs, sparking debate among investors. Some are viewing the current price as a buying opportunity, while others remain cautious.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom ($DXCM) is trending due to a short report by Hunterbrook Media alleging safety issues with its G7 glucose monitor, leading to a sharp stock decline. The community is debating the validity of the report, discussing potential buying opportunities amid the dip, and comparing Dexcom's products to competitors. Broader context includes concerns over the G7's accuracy, potential regulatory scrutiny, and Dexcom's position within the competitive diabetes management sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors discuss its potential to reach $100 amidst bullish sentiment and comparisons to other high-growth tech stocks. Community members are highlighting the company's involvement in AI infrastructure and data centers, with some speculating about potential news or announcements soon. There's also broader discussion around partnerships and contracts that could drive further growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Aquestive Therapeutics (AQST) on Thursday said that the U.S. Food and Drug Administration has informed the Company that an advisory committee meeting is not required for Anaphylm Sublingual Film.Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S., doing away with the need for injections. The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026.Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-will-not-require-advisory">said</a> that the company is encouraged by the FDA’s decision to waive a meeting and added that the company is “well-positioned” for launch. Shares of the company traded 17% higher in the premarket session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. A Stocktwits user opined that the stage is now set for approval of Anaphylm.<stembedurl>https://stocktwits.com/BioAmerica/message/627450441</stembedurl>Last month, Aquestive <a href="https://stocktwits.com/news-articles/markets/equity/aquestive-therapeutics-enters-75-million-dollar-funding-agreement/chsRkEVRdOO">said</a> that it entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP. The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Barber said that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.RTW, meanwhile, will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.AQST stock is up by 11% this year but down by about 7% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/ethereum-outperforms-bitcoin-while-broader-crypto-market-slips/chwd22IRdYJ">Ethereum Outperforms Bitcoin, While Broader Crypto Market Slips</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film

 The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026. 

Equity

 The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026. 


Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Aquestive Therapeutics, Inc. (AQST) on Thursday said that it has entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP, subject to U.S. Food and Drug Administration (FDA) approval of Anaphylm Sublingual Film.The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133251/0/en/Aquestive-Therapeutics-Announces-75M-Strategic-Funding-Agreement-with-RTW-to-Support-the-Potential-Launch-of-Anaphylm-epinephrine-Sublingual-Film.html">said</a> that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.Under the terms of the agreement, RTW will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 6% higher in the pre-market session.<figure class="image"><img style="aspect-ratio:631/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_7_57_19_AM_png_2d91151e35.webp" alt="AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="631" height="62"><figcaption>AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes uncertainty about funding is out of the way.<stembedurl>https://stocktwits.com/SonOfLionel19/message/625113435</stembedurl>Another, however, opined that the company would need more funds to launch the drug.<stembedurl>https://stocktwits.com/ae1213/message/625112218</stembedurl>Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S. The FDA is expected to decide on the candidate by January 31, 2026.Separately, the company also announced pricing of an underwritten offering of 21.25 million shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive are expected to be $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133263/0/en/Aquestive-Therapeutics-Announces-Pricing-of-85-Million-Underwritten-Offering-of-Common-Stock.html">said</a> it intends to use the net proceeds received from the offering primarily to advance the launch and commercialization of Anaphylm.AQST stock is up by 13% this year and by about 4% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-inks-up-to-1.3-billion-deal-with-superluminal-medicines/chsRS3IRdO7">Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail

Aquestive CEO Dan Barber said that the $75 million financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates

USANA Health (USNA) delivered earnings and revenue surprises of +37.04% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.13	--	--	N/A
Q2 '25	-$0.17	-$0.14	16.00%	BEAT
Q1 '25	-$0.17	-$0.24	-45.45%	MISSED
Q4 '24	-$0.13	-$0.19	-42.92%	MISSED
Q3 '24	-$0.12	-$0.13	-10.64%	MISSED

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AQST News

AQST Aquestive Therapeutics Inc